Ketamine Challenge Study With JNJ-40411813

NCT01101659 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Perceptual Disorders
Confusion
Schizophrenia

Interventions

DRUG: JNJ-40411813
DRUG: normal saline
DRUG: ketamine
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.